日前,默沙东(MSD)公布,其小分子疗法Welireg(belzutifan)在两项3期临床试验LITESPARK-011与LITESPARK-022中,用于治疗肾细胞癌(RCC)患者取得积极结果。基于上述数据,公司已向美国FDA递交相关监管申请。肾细胞癌是最常见的肾癌类型,约90%的肾癌确诊病例为RCC。2022年,全球约新增43.5万例肾癌病例,约15.6万例患者死于该疾病。RCC在男性中的...
Source Link日前,默沙东(MSD)公布,其小分子疗法Welireg(belzutifan)在两项3期临床试验LITESPARK-011与LITESPARK-022中,用于治疗肾细胞癌(RCC)患者取得积极结果。基于上述数据,公司已向美国FDA递交相关监管申请。肾细胞癌是最常见的肾癌类型,约90%的肾癌确诊病例为RCC。2022年,全球约新增43.5万例肾癌病例,约15.6万例患者死于该疾病。RCC在男性中的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.